The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10447 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether (ART)/lumefantrine (LUM)

Quality of fixed dose artemether/lumefantrine products in Jimma Zone, Ethiopia

July 15, 2019 - 16:14 -- Open Access
Author(s): 
Sileshi Belew, Sultan Suleman, Bart De Spiegeleer, et al.
Reference: 
Malaria Journal 2019 18:236, 15 July 2019

Malaria caused by Plasmodium vivax and Plasmodium falciparum is among the major public health problems in most endemic areas of the world. Artemisinin-based combination therapy (ACT) has been recommended as a first-line treatment for uncomplicated Plasmodium falciparum malaria almost in all endemic regions. Since ineffectively regulated medicines in resource limited settings could favour infiltration of poor quality anti-malarial medicines into pharmaceutical supply chain and jeopardize a positive treatment outcome, regular monitoring of the quality of anti-malarial medicines is critical. Thus, the aim of this study was to assess the quality of fixed dose combination (FDC) artemether (ART)/lumefantrine (LUM) tablets available in Jimma zone, Ethiopia.

Country: 
Subscribe to RSS - artemether (ART)/lumefantrine (LUM)